• Explore /
  • Poster
  • / Dabrafenib and trametinib in patients with tumors with <em>BRAF V600E/k</em> mutations: Updated results from NCI-MATCH arm H.

Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.

Abstract Poster

Authors

null

April K.S. Salama

Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Durham, NC

April K.S. Salama , Victoria Wang , Erin Renee Macrae , Jong-In Park , Helen X. Chen , Robert James Gray , Lisa McShane , Lawrence Rubinstein , P. Mickey Williams , Stanley R. Hamilton , Deborah Kay Armstrong , James V. Tricoli , Barbara A. Conley , Carlos L. Arteaga , Lyndsay Harris , Peter J. O'Dwyer , Alice P. Chen , Keith Flaherty

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04439292

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 3110)

DOI

10.1200/JCO.2024.42.16_suppl.3110

Abstract #

3110

Poster Bd #

255

Abstract Disclosures

Similar Posters

First Author: Manisha H. Shah

First Author: Gregory J. Riely

First Author: Johanna C. Bendell

First Author: Jonathan S. Cebon